Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 42 citations · 43 references
MedicineOncologyPathologyHematologic OncologyImmunopathologyMolecular OncologyAngiogenesisGrowth Factor SignalingLymphoid NeoplasmsLymphoid TissueLymphoid Tissue PathologyLymphoid TumorsLymphangiogenic SignalingNon-hodgkin Lymphoma TherapyPrognostic PredictionPrognostic VariablesVascular Endothelial Growth FactorVascular Endothelial Growth Factor ReceptorsVascular Endothelial Growth Factor SignalingVascular Endothelial Growth Factor-c Signaling
The aim of the study was to investigate the expression of angio- and lymphangiogenic molecules (vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4) in non-Hodgkin lymphomas (NHL) treated in the pre-rituximab era. Pre-therapeutic lymph-node biopsies from 155 patients with NHL (64 follicular lymphomas (FLs), 47 de novo diffuse large B-cell lymphomas (DLBCL) and 44 peripheral T-cell lymphomas (PTCL)) were stained by in situ hybridization and immunohistochemistry. Tumor cell expression of VEGF, VEGF-C and their receptors was detected in most of the analyzed biopsies. In FL, diffuse intratumoral VEGF staining correlated with shorter overall survival (OS) (p = 0.008) and diffuse KDR staining was associated with a higher risk of histologic transformation (p = 0.05). In DLBCL, high KDR expression predicted poor treatment response (p = 0.03) and had a significant adverse impact on OS (p < 0.001). In PTCL, diffuse tissue distribution of VEGF mRNA correlated with an unfavorable 5-year OS (p = 0.004).
43
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
New England Journal of Medicine · 1993 · 5K citations · Full text
Medicine, Oncology, Chemotherapy +15
Transplacental Carcinogenesis by Stilbestrol
Judah Folkman · New England Journal of Medicine · 1971 · 2.6K citations
Pharmacy, Oncology, Toxicology +17
Marc G. Achen, Michael Jeltsch, Eola Kukk et al. · Proceedings of the National Academy of Sciences · 1998 · 1.2K citations